financetom
Business
financetom
/
Business
/
What's Going On With Mullen Automotive Stock On Tuesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Mullen Automotive Stock On Tuesday?
May 26, 2025 7:05 AM

Mullen Automotive, Inc. ( MULN ) shares are trading higher on Tuesday after the electric vehicle manufacturer revealed a key legal development to resolve its longstanding dispute with GEM Yield Bahamas Limited and GEM Global Yield (GEM).

The company announced it had signed a settlement agreement with GEM on May 9, 2025. Under the deal, GEM will conduct a 55-day due diligence review, which may be extended at GEM’s discretion, to evaluate the transfer of Mullen’s Mishawaka, Indiana assets.

If completed, the transfer would fully satisfy the existing judgment. During this review period, all collection actions have been suspended.

Also Read: What’s Going On With NIO Stock On Tuesday?

David Michery, Chairman and CEO of Mullen, expressed optimism about the resolution, stating, “After four years of litigation, we have executed a settlement agreement which provides a path forward to a full resolution with GEM and puts this matter behind us.” He added, “I look forward to a great rest of 2025 and continued growth thereafter.”

The company continues expanding its core operations, particularly at its manufacturing site in Tunica, Mississippi. The facility supports scaling its electric commercial vehicle lineup to meet increasing demand.

In April, Mullen disclosed that Global Expert Shipping purchased its all-electric Mullen ONE Class 1 cargo van. The transaction is being handled through Mullen’s national dealership partner, Pritchard Automotive.

The buyer intends to integrate these EVs into its fleet to better align with sustainability goals, and additional orders are anticipated.

Price Action: MULN shares are trading higher by 5.50% to $0.1766 at the last check on Tuesday.

Read Next:

Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Supermicro Special Committee Finds No Evidence of Fraud; Shares Jump
Update: Supermicro Special Committee Finds No Evidence of Fraud; Shares Jump
Dec 2, 2024
10:19 AM EST, 12/02/2024 (MT Newswires) -- (Updates with additional information in the second and third paragraphs, and latest stock movement in the headline and last paragraph.) Super Micro Computer ( SMCI ) said Monday that an independent special committee found no evidence of misconduct or fraud on the part of management or the board of directors. The committee, formed...
Twilio Segment Expands AWS Partnership to Drive More Personalized Marketing Campaigns
Twilio Segment Expands AWS Partnership to Drive More Personalized Marketing Campaigns
Dec 2, 2024
10:21 AM EST, 12/02/2024 (MT Newswires) -- Twilio ( TWLO ) said Monday that Twilio Segment has expanded its integration with Amazon.com's ( AMZN ) Amazon Web Services, with Twilio Segment's Linked Audiences beta now publicly available for Amazon Redshift. Linked Audiences will help Amazon Redshift users drive personalized marketing campaigns that can boost engagement, said Twilio Segment President Thomas...
What's Going On With Nebius Shares Monday?
What's Going On With Nebius Shares Monday?
Dec 2, 2024
Nebius Group N.V. ( NBIS ) shares are trading higher on Monday after the company announced it entered into a $700 million private placement financing agreement. Here’s what you need to know. What To Know: The private placement aims to advance the company’s previously outlined plans to expand its comprehensive AI infrastructure, featuring large-scale GPU clusters, cloud platforms and developer-focused...
Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial
Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial
Dec 2, 2024
10:17 AM EST, 12/02/2024 (MT Newswires) -- Delcath Systems ( DCTH ) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer. The trial will evaluate the safety and efficacy of the combination therapy, with a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved